Sandoz Scores Regional First With EU Launch Of Autoinjectable Stelara Rival

The Approved Autoinjector Presentation Puts Sandoz Ahead Of Competition

Doubling down on the launch of its Stelara biosimilar Pyzchiva in Europe last year, Sandoz has just released an autoinjectable version of the drug, with the aim to offer a more convenient option for ustekinumab patients.

(Shutterstock)

Sandoz has landed a regional first with its launch of the Stelara (ustekinumab) biosimilar Pyzchiva in autoinjector form in Europe, putting it one step ahead of other players.

While the company has already launched Pyzchiva in the EU last year in different presentations, the autoinjector could offer a...

Welcome to Generics Bulletin

Create an account to read this article

More from Regulation

More from Generics Bulletin

Bakers And Fishermen: How Biosimilars Manufacturers Are Bridging The Skills Gap

 
• By 

At Medicines for Europe’s annual conference in Brussels, executives from Polpharma Biologics and Gedeon Richter spoke about the challenges in finding biosimilars manufacturing staff with the right backgrounds – and how they are looking to other industries to bridge the skills gap.

US Federal Circuit Says No To Teva And Viatris On Remanded Invega Sustenna Appeal

 
• By 

Just days after Viatris was frustrated in its attempts to challenge IP protecting Janssen’s Invega Trinza, the US Federal Circuit has rejected the firm’s and Teva’s bid to invalidate a patent shielding the one-month version of the brand, Invega Sustenna.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Generics Bulletin, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.